Federated Hermes, Inc. Puma Biotechnology, Inc. Transaction History

Federated Hermes, Inc.

$50.2 Billion
Q2 2025

A detailed history of Federated Hermes, Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 202,335 shares of PBYI stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

202,335

Previous 200,962 0.68%

Holding current value

$1.08 Million

Previous $594,000 16.84%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$2.74 - $3.72 $3,762 - $5,107	1,373 Added 0.68%	202,335 $694,000
Q1 2025 May 08, 2025	BUY	$2.76 - $3.88 $103,005 - $144,805	37,321 Added 22.81%	200,962 $594,000
Q4 2024 Feb 13, 2025	BUY	$2.42 - $3.39 $8,380 - $11,739	3,463 Added 2.16%	163,641 $499,000
Q3 2024 Nov 13, 2024	SELL	$2.25 - $4.03 $123 - $221	-55 Reduced 0.03%	160,178 $408,000
Q2 2024 Aug 08, 2024	SELL	$2.92 - $5.83 $2,017 - $4,028	-691 Reduced 0.43%	160,233 $522,000
Q1 2024 May 14, 2024	SELL	$4.29 - $7.4 $2,642 - $4,558	-616 Reduced 0.38%	160,924 $852,000
Q4 2023 Jan 31, 2024	SELL	$2.23 - $4.49 $45,494 - $91,600	-20,401 Reduced 11.21%	161,540 $699,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $23,717 - $32,656	-9,122 Reduced 4.77%	181,941 $642,000
Q1 2023 May 08, 2023	SELL	$2.21 - $4.82 $351,873 - $767,435	-159,219 Reduced 45.45%	191,063 $590,000
Q4 2022 Feb 13, 2023	SELL	$2.12 - $5.08 $10,782 - $25,836	-5,086 Reduced 1.43%	350,282 $1.48 Million
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $9,649 - $16,323	4,251 Added 1.21%	355,368 $842,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $17,479 - $35,171	10,658 Added 3.13%	351,117 $1 Million
Q1 2022 May 13, 2022	BUY	$2.13 - $3.24 $71,018 - $108,028	33,342 Added 10.86%	340,459 $981,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $28,254 - $65,234	9,914 Added 3.34%	307,117 $934,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $179,513 - $254,243	27,076 Added 10.02%	297,203 $2.08 Million
Q2 2021 Aug 16, 2021	SELL	$8.98 - $11.6 $5,468 - $7,064	-609 Reduced 0.22%	270,127 $2.48 Million
Q1 2021 May 13, 2021	SELL	$9.38 - $13.63 $315,233 - $458,063	-33,607 Reduced 11.04%	270,736 $2.63 Million
Q4 2020 Feb 12, 2021	SELL	$7.78 - $12.13 $1.05 Million - $1.63 Million	-134,534 Reduced 30.65%	304,343 $3.12 Million
Q3 2020 Nov 12, 2020	SELL	$9.5 - $11.14 $260,195 - $305,113	-27,389 Reduced 5.87%	438,877 $4.43 Million
Q2 2020 Aug 13, 2020	SELL	$7.01 - $13.24 $3.8 Million - $7.18 Million	-542,631 Reduced 53.78%	466,266 $4.86 Million
Q1 2020 May 13, 2020	BUY	$6.28 - $14.57 $1.16 Million - $2.69 Million	184,939 Added 22.45%	1,008,897 $8.52 Million
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $153,608 - $253,571	-23,632 Reduced 2.79%	823,958 $7.21 Million
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $2.95 Million - $4.34 Million	337,590 Added 66.19%	847,590 $9.12 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $9.69 Million - $28.2 Million	-787,759 Reduced 60.7%	510,000 $6.48 Million
Q1 2019 May 10, 2019	SELL	$20.77 - $42.37 $4.8 Million - $9.79 Million	-231,141 Reduced 15.12%	1,297,759 $50.3 Million
Q4 2018 Feb 13, 2019	BUY	$20.07 - $46.7 $28.9 Million - $67.2 Million	1,439,100 Added 1602.56%	1,528,900 $31.1 Million
Q2 2018 Aug 10, 2018	SELL	$48.3 - $68.25 $2.03 Million - $2.86 Million	-41,958 Reduced 31.84%	89,800 $5.31 Million
Q1 2018 May 09, 2018	BUY	$59.7 - $99.25 $3.34 Million - $5.55 Million	55,905 Added 73.7%	131,758 $8.97 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $3.61 Million - $5.1 Million	38,483 Added 102.98%	75,853 $0
Q3 2017 Nov 13, 2017	BUY	$72.0 - $119.75 $2.69 Million - $4.48 Million	37,370	37,370 $4.48 Million

Others Institutions Holding PBYI

# of Institutions

125

Shares Held

33.4M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $243M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Puma Biotechnology, Inc. Transaction History